(OTCQB: OTLC) (profile) are responding to this challenge with next-generation delivery platforms engineered to circumvent biological barriers and ensure direct, targeted access to the central nervous ...
CRISPR-edited tumor-infiltrating lymphocytes are emerging as a promising alternative to CAR T-cell therapy for solid cancers.
On March 20, the FDA approved Opdivo for adult and pediatric patients (aged 12 years and older) with previously untreated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results